Benitec Biopharma (Benitec Biopharma) Price-to-Tangible-Book : 0.34 (As of May. 05, 2024)

View and export this data going back to 2009. Start your Free Trial

What is Benitec Biopharma Price-to-Tangible-Book?

As of today (2024-05-05), Benitec Biopharma's share price is $0.01624. Benitec Biopharma's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $0.05. Hence, Benitec Biopharma's Price to Tangible Book Ratio of today is 0.34.

The historical rank and industry rank for Benitec Biopharma's Price-to-Tangible-Book or its related term are showing as below:

BNIKF' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.32 Med: 9.86 Max: 63.25
Current: 0.32

During the past 11 years, Benitec Biopharma's highest Price to Tangible Book Ratio was 63.25. The lowest was 0.32. And the median was 9.86.

BNIKF's Price-to-Tangible-Book is ranked better than
73.81% of 1222 companies
in the Biotechnology industry
Industry Median: 2.715 vs BNIKF: 0.32

A closely related ratio is called PB Ratio. As of today, Benitec Biopharma's share price is $0.01624. Benitec Biopharma's Book Value per Sharefor the quarter that ended in Dec. 2023 was $0.05. Hence, Benitec Biopharma's P/B Ratio of today is 0.34.

Benitec Biopharma Price-to-Tangible-Book Historical Data

The historical data trend for Benitec Biopharma's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma Price-to-Tangible-Book Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Price-to-Tangible-Book

Get a 7-Day Free Trial

0.62

Benitec Biopharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Tangible-Book	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Benitec Biopharma's Price-to-Tangible-Book

For the Biotechnology subindustry, Benitec Biopharma's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's Price-to-Tangible-Book falls into.

Benitec Biopharma Price-to-Tangible-Book Calculation

Benitec Biopharma's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Dec. 2023 )
	=	0.01624	/	0.048
	=	0.34

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Benitec Biopharma Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (Benitec Biopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (OTCPK:BNIKF) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

BNTC:USA

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.